Several clinical trials and observational studies have shown that the use of PARP inhibitors significantly decreases the risk of recurrence among patients with advanced ovarian cancer, making it one of the most important parts of maintenance therapy [22]. This evidence concerns the gene PARP1 and ovarian cancer.